English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/110035
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Potent and selective MAO-B inhibitory activity: Amino- versus nitro-3-arylcoumarin derivatives

AuthorsMatos, M. J.; Rodríguez-Enríquez, F.; Vilar, S.; Santana, Lourdes; Uriarte, E.; Hripcsak, G.; Estrada, Martín ; Rodríguez-Franco, María Isabel ; Viña, D.
Keywords3-Arylcoumarins
Perkin reaction
Monoamine oxidase inhibitors
PAMPA assay
ADME theoretical properties
Docking studies
Issue Date2015
PublisherElsevier
CitationBioorganic and Medicinal Chemistry Letters 25: 642-648 (2015)
AbstractIn this study we synthesized and evaluated a new series of amino and nitro 3-arylcoumarins as hMAO-A and hMAO-B inhibitors. Compounds 2, 3, 5 and 6 presented a better activity and selectivity profile against the hMAO-B isoform (IC50 values between 2 and 6 nM) than selegiline. In general, the amino derivatives (4-6) proved to be more selective against MAO-B than the nitro derivatives (1-3). Additionally, a theoretical study of some physicochemical properties, PAMPA and reversibility assays for the most potent derivative, and molecular docking simulations were carried out to further explain the pharmacological results, and to identify the hypothetical binding mode for the compounds inside the hMAO-B.
URIhttp://hdl.handle.net/10261/110035
DOI10.1016/j.bmcl.2014.12.001
Identifiersdoi: 10.1016/j.bmcl.2014.12.001
issn: 0960-894X
e-issn: 1464-3405
Appears in Collections:(IQM) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Publ 66 (Potent and selective MAO-B inhibitory activity).pdf387,01 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.